In Japanese blood donors, positivity for antibodies to hepatitis C virus (HCV) ranges from 0-2% in subjects under 20 to 3.9% in those over 50 years. It is estimated that at least 2-3 million Japanese have contracted HCV infection through contaminated blood. HCV carrier state was confirmed by polymerase chain reaction for HCV-RNA in subjects positive for antibodies to more than one viral protein (70% of cases).
Abstract
In Japanese blood donors, positivity for antibodies to hepatitis C virus (HCV) ranges from 0-2% in subjects under 20 to 3.9% in those over 50 years. It is estimated that at least 2-3 million Japanese have contracted HCV infection through contaminated blood. HCV carrier state was confirmed by polymerase chain reaction for HCV-RNA in subjects positive for antibodies to more than one viral protein (70% of cases). Subjects positive for core antibody alone, however, were found to be HCV-RNA negative with normal liver function, and are considered to have only a past history of HCV infection (30% of cases). Acute hepatitis C progresses to chronic infection in about 90% of cases. In comparison with hepatitis B, chronic hepatitis C leads more frequently to cirrhosis and liver cancer, and rarely remits spontaneously. In typical HCV infection, aminotransferase activities fluctuate markedly in the early stages, then become relatively stable for 10 years or more, with chronic persistent hepatitis shown by histological examination. Thereafter, aminotransferase activities may change dramatically, with progression to chronic active hepatitis and rapid development of cirrhosis and hepatocellular carcinoma. On average, it takes about 30 years for chronic hepatitis C to progress from initial infection to cirrhosis and cancer, but the disease progresses much more rapidly in elderly patients. blood was carried out in blood banks across Japan using first generation enzyme linked immunosorbent assays (ELISAs) for anti-HCV.' -In February 1992, this screening procedure was changed to a new one using the second generation anti-HCV assay that works on the principle of passive haemaggluination. This is because the first generation assay, the anti-clOO-3 antibody-detecting ELISA, has a low sensitivity and leads to a number of false positives. The second generation anti-HCV assay uses three epitopes, namely core region c22, non-structural region c33c, and the c100-3 antigen used in the first generation kit (Fig 1) . Figure 2 shows the changes in aminotransferase activities and anti-HCV values for a typical patient with hepatitis C infection. After fluctuating changes in ALT values and AST activities at an early stage of infection, the hepatitis enters a relatively stable period. Thereafter, dramatic changes in ALT and AST may follow after five or 10 years, with progression to cirrhosis of the liver. Figure 2 shows that patients progressed from chronic persistent hepatitis to chronic active hepatitis 2A (moderate), chronic active hepatitis 2B (severe), and eventually to cirrhosis of the liver. Careful study of the clinical course from onset of infection to cirrhosis and liver cancer indicates that hepatitis C is typified by constant improvements and exacerbations in both symptoms and liver function tests. Figure 3 compares 22 cases of hepatitis C with 30 cases of hepatitis B in terms of clinical staging using liver biopsies, on three or more occasions over 15 years. In typical cases of hepatitis C, chronic persistent hepatitis continues for more than 10 years after the onset of disease, after which it progresses rapidly through chronic active hepatitis to cirrhosis of the liver. In contrast, most cases of hepatitis B advance to hepatic cirrhosis within four or five years of the diagnosis of chronic hepatitis. Table IV shows the progression of chronic hepatitis to cirrhosis, according to the stage of fibrosis at repeated liver biopsy. The diagnosis of chronic hepatitis was divided into four stages according to the grade of portal fibrosis. It is clear that the time between diagnosis and onset of hepatic cirrhosis is much shorter for hepatitis B than for hepatitis C.
Age plays a major part in the progression of hepatitis C. Figure 4 illustrates the relation between the age of patients at transfusion and the serial histological progression of hepatitis C over more than 10 years. Cases of juvenile transfusion progress gradually from chronic hepatitis to cirrhosis of the liver, whereas transfusion in the elderly is associated with a more rapid progression to liver cirrhosis. Thus, F3 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 Long term prognosis of hepatitis C Table V presents figures for the long term prognosis of 155 cases of chronic hepatitis C, and 173 cases of chronic hepatitis B (positive for hepatitis B e antigen (HBeAg) at the first examination). Patients were followed up for an average study period of 8&7 years. Chronic hepatitis C progressed to liver cirrhosis and liver cancer in 29-7% and 14-8% of cases, respectively. Only 2-6% of patients were considered clinically cured. Of the 173 cases with chronic hepatitis B, 17.3% progressed to cirrhosis of the liver and 4.6% to liver cancer, while 38-2% were cured. Thus, there seems to be two distinct types of chronic hepatitis B: one progresses to liver cirrhosis or cancer, while the other remits spontaneously. In contrast, very few cases of hepatitis C are cured naturally, and most progress to cirrhosis of the liver and liver cancer. Compared with hepatitis B, therefore, patients with hepatitis C have a poor prognosis.3 Figure 5 shows the results of a survey of patients with transfusion associated HCV infection: (a) 28 cases of liver cancer progressing from cirrhosis; and (b) 32 cases of liver cancer diagnosed at the first examination. In both groups, 80% of patients progressed to liver cancer 20-35 years after transfusion (average 26 years). Thus, the average duration of chronic HCV infection is about 30 years.
Conclusion
In Japan, about 2-3 million people are infected with the hepatitis C virus. Of these, about 70% are HCV carriers; the remaining 30% are positive for anti-HCV core antibody alone which, together with HCV-RNA negativity on PCR, may be evidence of past HCV infection. Once someone is chronically infected with HCV, there is little chance of spontaneous remission and the disease gradually worsens over long periods of time. The disease progresses slowly in young patients, while the elderly show a rapid progress from chronic hepatitis C to liver cirrhosis and liver cancer. The clinical course lasts an average of 30 years from infection to cirrhosis and possibly hepatocellular carcinoma. As infection with HCV can lead to liver cancer, it is important to diagnose these patients early and to start effective treatment.
